CD19/CD20 dual-targeted chimeric antigen receptor-engineered natural killer cells exhibit improved cytotoxicity against acute lymphoblastic leukemia
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
CD19/CD20 dual-targeted chimeric antigen receptor-engineered natural killer cells exhibit improved cytotoxicity against acute lymphoblastic leukemia ; volume:22 ; number:1 ; day:13 ; month:3 ; year:2024 ; pages:1-15 ; date:12.2024
Journal of translational medicine ; 22, Heft 1 (13.3.2024), 1-15, 12.2024
- Urheber
-
Yang, Na
Zhang, Caili
Zhang, Yingchun
Fan, Yuting
Zhang, Jing
Lin, Xiaojin
Guo, Ting
Gu, Yangzuo
Wu, Jieheng
Gao, Jianmei
Zhao, Xing
He, Zhixu
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12967-024-04990-6
- URN
-
urn:nbn:de:101:1-2405152104182.675630053391
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:55 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Yang, Na
- Zhang, Caili
- Zhang, Yingchun
- Fan, Yuting
- Zhang, Jing
- Lin, Xiaojin
- Guo, Ting
- Gu, Yangzuo
- Wu, Jieheng
- Gao, Jianmei
- Zhao, Xing
- He, Zhixu
- SpringerLink (Online service)
Ähnliche Objekte (12)
Novel CD19 chimeric antigen receptor T cells manufactured next-day for acute lymphoblastic leukemia
Advances of CD19-directed chimeric antigen receptor-modified T cells in refractory/relapsed acute lymphoblastic leukemia
Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia
A CD19/Fc fusion protein for detection of anti-CD19 chimeric antigen receptors
A retrospective comparison of CD19 single and CD19/CD22 bispecific targeted chimeric antigen receptor T cell therapy in patients with relapsed/refractory acute lymphoblastic leukemia
CD20 and CD19 targeted vectors induce minimal activation of resting B lymphocytes
CD19 and CD20 Targeted Vectors Induce Minimal Activation of Resting B Lymphocytes
High cytotoxic efficiency of lentivirally and alpharetrovirally engineered CD19-specific chimeric antigen receptor natural killer cells against acute lymphoblastic leukemia
Infectious complications in pediatric patients undergoing CD19+CD22+ chimeric antigen receptor T-cell therapy for relapsed/refractory B-lymphoblastic leukemia
The efficacy and safety of anti-CD19/CD20 chimeric antigen receptor- T cells immunotherapy in relapsed or refractory B-cell malignancies:a meta-analysis
Chimeric Antimicrobial Peptides Exhibit Multiple Modes of Action
Co-infusion of haplo-identical CD19-chimeric antigen receptor T cells and stem cells achieved full donor engraftment in refractory acute lymphoblastic leukemia
Novel CD19 chimeric antigen receptor T cells manufactured next-day for acute lymphoblastic leukemia
Advances of CD19-directed chimeric antigen receptor-modified T cells in refractory/relapsed acute lymphoblastic leukemia
Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia
A CD19/Fc fusion protein for detection of anti-CD19 chimeric antigen receptors
A retrospective comparison of CD19 single and CD19/CD22 bispecific targeted chimeric antigen receptor T cell therapy in patients with relapsed/refractory acute lymphoblastic leukemia
CD20 and CD19 targeted vectors induce minimal activation of resting B lymphocytes
CD19 and CD20 Targeted Vectors Induce Minimal Activation of Resting B Lymphocytes
High cytotoxic efficiency of lentivirally and alpharetrovirally engineered CD19-specific chimeric antigen receptor natural killer cells against acute lymphoblastic leukemia
Infectious complications in pediatric patients undergoing CD19+CD22+ chimeric antigen receptor T-cell therapy for relapsed/refractory B-lymphoblastic leukemia
The efficacy and safety of anti-CD19/CD20 chimeric antigen receptor- T cells immunotherapy in relapsed or refractory B-cell malignancies:a meta-analysis
Chimeric Antimicrobial Peptides Exhibit Multiple Modes of Action
Co-infusion of haplo-identical CD19-chimeric antigen receptor T cells and stem cells achieved full donor engraftment in refractory acute lymphoblastic leukemia
Novel CD19 chimeric antigen receptor T cells manufactured next-day for acute lymphoblastic leukemia
Advances of CD19-directed chimeric antigen receptor-modified T cells in refractory/relapsed acute lymphoblastic leukemia
Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia
A CD19/Fc fusion protein for detection of anti-CD19 chimeric antigen receptors
A retrospective comparison of CD19 single and CD19/CD22 bispecific targeted chimeric antigen receptor T cell therapy in patients with relapsed/refractory acute lymphoblastic leukemia
CD20 and CD19 targeted vectors induce minimal activation of resting B lymphocytes
CD19 and CD20 Targeted Vectors Induce Minimal Activation of Resting B Lymphocytes
High cytotoxic efficiency of lentivirally and alpharetrovirally engineered CD19-specific chimeric antigen receptor natural killer cells against acute lymphoblastic leukemia
Infectious complications in pediatric patients undergoing CD19+CD22+ chimeric antigen receptor T-cell therapy for relapsed/refractory B-lymphoblastic leukemia
The efficacy and safety of anti-CD19/CD20 chimeric antigen receptor- T cells immunotherapy in relapsed or refractory B-cell malignancies:a meta-analysis
Chimeric Antimicrobial Peptides Exhibit Multiple Modes of Action